Bayer Collaborates with MOMA Therapeutics for the Development of a Small Molecule Oncology Program
Shots:
- Bayer and MOMA Therapeutics have signed an exclusive licensing agreement for the development & commercialization of a small molecule using MOMA’s KNOMATIC platform in oncology
- Bayer will be able to access to the program & insights generated through MOMA’s KNOMATIC platform plus will handle further preclinical, clinical & commercial events. The platform combines deep structural insights, advanced hit-finding & computational optimization for the discovery of leads targeting dynamic proteins
- MOMA will get an upfront, collaboration fee plus near-term discovery, development & commercial milestones along with net-sales-based tiered royalties. Financial details were undisclosed
Ref: Bayer | Image: Bayer & MOMA Therapeutics
Related News:- Bayer Reports Regulatory Submission of Nubeqa to the US FDA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
